End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
21,228 ARS | +2.75% | +6.00% | +7.38% |
Business Summary
- sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);
- other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.
Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
Number of employees: 18,000
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Innovative Medicines
100.0
%
| 27,281 | 100.0 % | 27,116 | 100.0 % | -0.60% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
71.7
%
| 18,884 | 69.2 % | 19,438 | 71.7 % | +2.93% |
Europe
15.9
%
| 4,469 | 16.4 % | 4,310 | 15.9 % | -3.56% |
Other International
12.4
%
| 3,928 | 14.4 % | 3,368 | 12.4 % | -14.26% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Daniel O'Day
CEO | Chief Executive Officer | 59 | 01/19/01 |
Andrew Dickinson
DFI | Director of Finance/CFO | 54 | 01/16/01 |
Flavius Martin
CTO | Chief Tech/Sci/R&D Officer | - | 12/21/12 |
Merdad Parsey
CTO | Chief Tech/Sci/R&D Officer | 61 | 01/19/01 |
Jacquie Ross
IRC | Investor Relations Contact | - | 01/21/01 |
Adam Levy
PRN | Corporate Officer/Principal | - | - |
Stacey Ma
PRN | Corporate Officer/Principal | 54 | 18/22/18 |
Tomas Cihlar
PRN | Corporate Officer/Principal | 57 | - |
Jyoti Mehra
HRO | Human Resources Officer | 48 | 01/17/01 |
Joydeep Ganguly
PRN | Corporate Officer/Principal | - | 01/19/01 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Anthony Welters
BRD | Director/Board Member | 69 | 17/20/17 |
Director/Board Member | 71 | 01/18/01 | |
Ted Love
BRD | Director/Board Member | 65 | 01/02 |
Director/Board Member | 70 | 09/18/09 | |
Javier Rodriguez
BRD | Director/Board Member | 53 | 15/20/15 |
Daniel O'Day
CEO | Chief Executive Officer | 59 | 01/19/01 |
Sandra Horning
BRD | Director/Board Member | 75 | 28/20/28 |
Kelly Kramer
BRD | Director/Board Member | 56 | 19/16/19 |
Director/Board Member | 70 | 07/20/07 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 1,245,853,209 | 1,244,427,084 ( 99.89 %) | 0 | 99.89 % |
Holdings
Name | Equities | % | Valuation |
---|---|---|---|
ARCUS BIOSCIENCES, INC. 34.67% | 31,532,781 | 34.67% | 475,199,010 $ |
GALAPAGOS NV 25.35% | 16,707,477 | 25.35% | 466,862,710 $ |
ARCELLX, INC. 12.56% | 6,720,803 | 12.56% | 349,481,756 $ |
4,126,119 | 9.57% | 51,700,271 $ | |
TANGO THERAPEUTICS, INC. 4.54% | 4,854,443 | 4.54% | 33,592,746 $ |
ASSEMBLY BIOSCIENCES, INC. 19.76% | 1,089,468 | 19.76% | 16,505,440 $ |
HOOKIPA PHARMA INC. 19.43% | 18,759,465 | 19.43% | 14,895,015 $ |
LEAP THERAPEUTICS, INC. 13.90% | 5,319,148 | 13.90% | 12,925,530 $ |
ALLOVIR, INC. 14.47% | 16,635,286 | 14.47% | 12,559,641 $ |
XILIO THERAPEUTICS, INC. 19.90% | 7,345,473 | 19.90% | 7,933,111 $ |
Company contact information
Group companies
Name | Category and Sector |
---|---|
Gilead Sciences Ireland UC
| |
Gilead Therapeutics A1 Unlimited Co.
Gilead Therapeutics A1 Unlimited Co. Pharmaceuticals: MajorHealth Technology Part of Gilead Sciences, Inc., Gilead Therapeutics A1 Unlimited Co. is an Irish company that develops and manufactures pharmaceutical medicines. The company is located in Ireland. |
Pharmaceuticals: Major
|
Sector
Sales per region
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+45.82% | 765B | |
-6.16% | 354B | |
+19.86% | 331B | |
+9.32% | 299B | |
+18.85% | 248B | |
-1.02% | 219B | |
+10.95% | 216B | |
+5.90% | 164B | |
-0.73% | 162B |
- Stock Market
- Equities
- GILD Stock
- GILD Stock
- Company Gilead Sciences, Inc.